Vanda Pharmaceuticals (VNDA) Stock Price, News & Analysis

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) is a biopharmaceutical company in the pharmaceutical preparation manufacturing industry focused on the development and commercialization of therapies for high unmet medical needs. According to company disclosures and recent regulatory updates, Vanda concentrates on neurologic, psychiatric, dermatologic, sleep, and inflammatory conditions, combining commercialized medicines with a late-stage and mid-stage pipeline.

Vanda’s commercial portfolio includes HETLIOZ, Fanapt, PONVORY and NEREUS (tradipitant). HETLIOZ (tasimelteon) is described by the company as a melatonin‑receptor agonist approved in the United States for the treatment of Non‑24‑Hour Sleep‑Wake Disorder and nighttime sleep disturbances associated with Smith‑Magenis Syndrome. Fanapt is referenced in company financial reports as a key product for the treatment of schizophrenia, and management highlights Fanapt net product sales growth and prescription growth as important commercial metrics. PONVORY is cited as part of Vanda’s anti‑inflammatory and neurology portfolio and is referenced in connection with relapsing forms of multiple sclerosis and clinical development for psoriasis and ulcerative colitis.

NEREUS (tradipitant) is a neurokinin‑1 (NK‑1) receptor antagonist licensed by Vanda from Eli Lilly and Company. The U.S. Food and Drug Administration (FDA) has approved NEREUS for the prevention of vomiting induced by motion in adults, and Vanda describes this as the first new pharmacologic treatment in motion sickness in over four decades. Company communications emphasize that NEREUS is also in clinical development for gastroparesis and for the prevention of nausea and vomiting induced by GLP‑1 receptor agonists, reflecting Vanda’s focus on conditions involving substance P‑mediated pathways.

Beyond its marketed products, Vanda reports an active pipeline of investigational therapies. Imsidolimab, a fully humanized IgG4 IL‑36 receptor antagonist licensed from AnaptysBio, is being developed for generalized pustular psoriasis (GPP), a rare, life‑threatening autoinflammatory skin disorder. Vanda has submitted a Biologics License Application (BLA) to the FDA for imsidolimab in GPP, supported by Phase 3 GEMINI‑1 and GEMINI‑2 studies that, according to the company, showed rapid and durable disease clearance with a favorable safety profile.

Vanda also highlights Bysanti (milsaperidone), for which a New Drug Application (NDA) is under FDA review for bipolar I disorder and schizophrenia. The company notes an ongoing Phase III clinical study of Bysanti as a once‑daily adjunctive treatment for major depressive disorder. In addition, Vanda is developing a long‑acting injectable formulation of iloperidone for schizophrenia relapse‑prevention and for treatment‑resistant hypertension, with clinical studies enrolling or planned according to its public updates.

In regulatory interactions, Vanda has described a collaborative framework with the FDA covering HETLIOZ and tradipitant. Under this framework, the FDA agreed to expedited re‑reviews of a partial clinical hold on long‑term tradipitant studies in motion sickness and of a supplemental New Drug Application (sNDA) for HETLIOZ in jet lag disorder. The company reports that the FDA has lifted the partial clinical hold on a long‑term tradipitant protocol for motion sickness after concluding that motion sickness is an acute, event‑driven condition. Vanda also reports receiving an FDA decision letter stating that the HETLIOZ sNDA for jet lag disorder could not be approved in its current form, while acknowledging positive efficacy signals from controlled clinical trials; Vanda has publicly stated that it disagrees with the FDA’s interpretation and intends to continue engagement.

Vanda characterizes itself in multiple press releases as a global biopharmaceutical company focused on therapies for high unmet medical needs and on improving patients’ lives. Earlier descriptions of its business state that the company derives a majority of revenue from Fanapt product sales and that it sells products predominantly in the United States, with additional sales in Israel, Europe, and Canada. The company’s activities span late‑stage clinical development, regulatory submissions (NDAs and BLAs), and commercialization of approved medicines.

Through its combination of marketed products—HETLIOZ, Fanapt, PONVORY, and NEREUS—and a pipeline that includes imsidolimab, Bysanti, tradipitant in additional indications, and long‑acting iloperidone formulations, Vanda positions itself as a therapeutics developer working across sleep‑wake disorders, psychiatric conditions, motion sickness, inflammatory skin disease, and gastrointestinal or treatment‑related nausea and vomiting.

Business focus and therapeutic areas

Based on company statements, Vanda’s work centers on:

• Sleep and circadian rhythm disorders through HETLIOZ and its exploration in jet lag disorder.
• Psychiatric and neurologic disorders via Fanapt, Bysanti, PONVORY‑related programs, and long‑acting iloperidone.
• Motion sickness and emesis with NEREUS (tradipitant) for vomiting induced by motion and ongoing studies in GLP‑1‑induced nausea and vomiting.
• Rare inflammatory dermatologic disease with imsidolimab for generalized pustular psoriasis.

Across these areas, Vanda emphasizes high unmet medical need, rare orphan disorders, and conditions where existing therapies may be limited or poorly tolerated.

Regulatory and commercial profile

Vanda’s disclosures highlight multiple concurrent regulatory reviews, including NDAs for Bysanti and tradipitant in motion sickness and a BLA for imsidolimab. The company also reports investing in commercial infrastructure and brand visibility to support its marketed products and potential future launches. Financial reports attribute total net product sales to Fanapt, HETLIOZ, and PONVORY, and discuss growth in Fanapt prescriptions and sales.